Shopping Cart

Your shopping cart is currently empty

Oxodipine

Name: Oxodipine
Brand: TargetMol
SKU: T68123
Price: 46 USD
Availability: InStock
Rating: 5 (10 reviews)

🥰Excellent

Catalog No. T68123Cas No. 90729-41-2

Oxodipine, a dihydropyridine-type calcium antagonist, inhibited KCl-induced aortic contraction in rabbits and reduced cardiac force in less potent rat ventricular test-paper contractions. In rat cultured neonatal ventricular myocytes, Oxodipine reduced L-type Ca currents (I) with an IC of 0.24 μM, and against T-type Ca currents (I) with an IC of 0.41 μM. Oxodipine causes constipation in mice and gingival hyperplasia in dogs.

Oxodipine

🥰Excellent

Purity: 99.64%

Catalog No. T68123Cas No. 90729-41-2

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$46	In Stock	In Stock
5 mg	$106	In Stock	In Stock
10 mg	$156	In Stock	In Stock
25 mg	$303	In Stock	In Stock
50 mg	$413	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products. If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.

Questions

Batch Information

Select Batch

Purity:99.64%

Appearance:Solid

Color:White

Resource Download

COA LCMS HNMR

Product Introduction

Bioactivity

Description	Oxodipine, a dihydropyridine-type calcium antagonist, inhibited KCl-induced aortic contraction in rabbits and reduced cardiac force in less potent rat ventricular test-paper contractions. In rat cultured neonatal ventricular myocytes, Oxodipine reduced L-type Ca currents (I) with an IC of 0.24 μM, and against T-type Ca currents (I) with an IC of 0.41 μM. Oxodipine causes constipation in mice and gingival hyperplasia in dogs.
Targets&IC50	I(CaL):0.24 µM
In vitro	In aortic rings, Oxodipine (10(-11)-10(-6) M) inhibited in a concentration-dependent manner the contractions induced by high K+ (IC50 = 9.0 +/- 4.0 x 10(-10) M) or by Ca2+ in high K+ solution (IC50 = 6.2 +/- 2.4 x 10(-9) M). In mesenteric resistance vessels, Oxodipine inhibited the contractions induced by high K+(IC50 = 5.2 +/- 3.1 x 10(-10)).[4]
In vivo	Oxodipine (5, 20, and 50 μg/kg; anesthetized dogs), a new dihydropyridine calcium channel blocker, ineffective at 5 μg/kg, whereas doses of 20 and 50 μg/kg of oxodipine elicited a decrease in blood pressure with no change in heart rate. These results suggest that, in contrast to other first-generation dihydropyridines, oxodipine exerts a relatively specific action on blood vessels without significant intrinsic negative chronotropic properties in anesthetized sinoaortic-denervated dogs.[4]

Chemical Properties

Molecular Weight	359.37
Formula	C₁₉H₂₁NO₆
Cas No.	90729-41-2
Smiles	C(OCC)(=O)C=1C(C(C(OC)=O)=C(C)NC1C)C2=C3C(=CC=C2)OCO3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 55 mg/mL (153.05 mM), Sonication is recommended.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.7826 mL	13.9132 mL	27.8265 mL	139.1324 mL
5 mM	0.5565 mL	2.7826 mL	5.5653 mL	27.8265 mL
10 mM	0.2783 mL	1.3913 mL	2.7826 mL	13.9132 mL
20 mM	0.1391 mL	0.6957 mL	1.3913 mL	6.9566 mL
50 mM	0.0557 mL	0.2783 mL	0.5565 mL	2.7826 mL
100 mM	0.0278 mL	0.1391 mL	0.2783 mL	1.3913 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc